Trial Profile
Randomized Phase 2 Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary)
- Indications Bladder cancer; Carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 01 Nov 2023 Primary endpoint has been met, (the positive predictive value of cCR for a composite outcome), as per Results published in the Nature Medicine
- 01 Nov 2023 Results published in the Nature Medicine
- 10 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Jul 2023.